HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The cell cycle profiling-risk score based on CDK1 and 2 predicts early recurrence in node-negative, hormone receptor-positive breast cancer treated with endocrine therapy.

Abstract
The Cell Cycle Profiling - Risk Score (C2P-RS) based on CDK1 and CDK2 specific activities was significantly associated with relapse in breast cancers. We evaluated the prognostic value of the C2P-RS classification using a Japanese cohort including node-negative, hormone receptor-positive breast cancers treated with adjuvant endocrine therapy alone as systemic therapy. Of 266 patients, 22 (8.3%) relapsed within 5 years after surgery. The distribution of each C2P-RS group was 71.8% in the low group, 12.0% in the intermediate group, and 16.2% in the high group. The 5-year relapse-free survival rate in the low C2P-RS group (97.3%) was significantly higher than that in the intermediate C2P-RS group (84.3%) or the high C2P-RS group (74.4%) (P < 0.001). The univariate analysis demonstrated that age, tumor size, histologic grade, and HER2 had no significant correlations with relapse but the C2P-RS classification (P < 0.001) and Ki-67 (P = 0.009) were significantly associated with relapse. Multivariate analysis showed only that the C2P-RS classification was a significant independent prognostic indicator. The C2P-RS classification might be a significant predictor of earlier recurrence in node-negative, hormone receptor-positive breast cancers treated with endocrine therapy.
AuthorsSeung Jin Kim, Norikazu Masuda, Fumine Tsukamoto, Hideo Inaji, Futoshi Akiyama, Hiroshi Sonoo, Junichi Kurebayashi, Katsuhide Yoshidome, Masahiko Tsujimoto, Hiroyuki Takei, Shinobu Masuda, Seigo Nakamura, Shinzaburo Noguchi
JournalCancer letters (Cancer Lett) Vol. 355 Issue 2 Pg. 217-23 (Dec 28 2014) ISSN: 1872-7980 [Electronic] Ireland
PMID25218592 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Antineoplastic Agents, Hormonal
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Receptor, ErbB-2
  • CDC2 Protein Kinase
  • CDK1 protein, human
  • CDK2 protein, human
  • Cyclin-Dependent Kinase 2
  • Cyclin-Dependent Kinases
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal (therapeutic use)
  • Breast Neoplasms (drug therapy, genetics, metabolism, pathology)
  • CDC2 Protein Kinase
  • Cell Cycle (genetics, physiology)
  • Chemotherapy, Adjuvant (methods)
  • Cyclin-Dependent Kinase 2 (genetics, metabolism)
  • Cyclin-Dependent Kinases (genetics, metabolism)
  • Disease-Free Survival
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local (enzymology, genetics, metabolism, pathology)
  • Prognosis
  • Receptor, ErbB-2 (genetics, metabolism)
  • Receptors, Estrogen (metabolism)
  • Receptors, Progesterone (metabolism)
  • Retrospective Studies
  • Risk
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: